Penn Medicine Provider
Hematology
Alfred L. Garfall, MD
4.9
(490)
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West

About me

  • Director, Autologous Hematopoietic Stem Cell Transplantation
  • Section Chief, Myeloma, Hematology-Oncology
  • Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

Education and training

  • Medical School: New York University School of Medicine
  • Residency: Massachusetts General Hospital/Brigham and Women’s Hospital
  • Fellowship: Hospital of the University of Pennsylvania

What my patients think about me

Average Rating
4.9

490 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

May 2025
5.0
5.0
dr. garfall is the best
May 2025
5.0
5.0
excellent bedside manner
May 2025
5.0
5.0
i felt very comfortable with dr. garfall
May 2025
5.0
5.0
i really like him

Insurance accepted

My Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Garfall is a Penn Medicine physician.

Qualifications and experience

My research

Garfall AL, Cohen AD, Susanibar-Adaniya SP, Hwang WT, Vogl DT, Waxman AJ, Lacey SF, Gonzalez VE, Fraietta JA, Gupta M, Kulikovskaya I, Tian L, Chen F, Koterba N, Bartoszek RL, Patchin M, Xu R, Plesa G, Siegel DL, Brennan A, Nelson AM, Ferthio R, Cosey A, Shea KM, Leskowitz R, Four M, Wilson WV, Miao F, Lancaster E, Carreno BM, Linette GP, Hexner EO, Young RM, Bu D, Mansfield KG, Brogdon JL, June CH, Milone MC, Stadtmauer EA. Anti-BCMA/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy , Blood Cancer Discov, BCD(22): 2022,0074


Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martínez-López J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in Relapsed or Refractory Multiple Myeloma , N Engl J Med, 387(6): 2022,495-505


Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, Clurman A, Dwomoh E, Armijo G, Gomes ALC, Littmann ER, Schluter J, Fontana E, Taur Y, Park JH, Palomba ML, Halton E, Ruiz J, Jain T, Pennisi M, Afuye AO, Perales MA, Freyer CW, Garfall A, Gier S, Nasta S, Landsburg D, Gerson J, Svoboda J, Cross J, Chong EA, Giralt S, Gill SI, Riviere I, Porter DL, Schuster SJ, Sadelain M, Frey N, Brentjens RJ, June CH, Pamer EG, Peled JU, Facciabene A, van den Brink MRM, Ruella M. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy , Nat Med, 28(4): 2022,713-723


Usmani SZ, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Rosinol L, Chari A, Bhutani M, Karlin L, Benboubker L, Pei L, Verona R, Girgis S, Stephenson T, Elsayed Y, Infante J, Goldberg JD, Banerjee A, Mateos MV, Krishnan A. Teclistamab, a B-cell maturation antigen X CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma MajesTEC-1: a multicentre, open-label, single-arm, phase 1 study , Lancet, 398(10301): 2021,665-674


Garfall A, Cohen A, Stadtmauer E, Susanibar-Adaniya S, Vogl D, Waxman A Overall Survival Remains Important in Trials of Early-Line Multiple Myeloma Therapy , Journal of Clinical Oncology, 40(1): 2021,106-107


Garfall A, Dancy E, Cohen A, Wang WH, Frai J, Suhoski M, Levine B, Siegel D, Stadtmauer E, Vogl D, Waxman A, Rapoport A, Milone M, June C, Melehorst J T cell phenotypes associated with effective CAR T cell therapy in post-induction versus relapsed multiple myeloma , Blood Adv , 3(19): 2019 ,2812-2815


Cohen AD, Garfall AL, Stadtmauer EA, Melenhorst JJ, Lacey SF, Lancaster E, Vogl DT, Weiss BM, Dengel K, Nelson A, Plesa G, Chen F, Davis MM, Hwang WT, Young RM, Brogdon JL, Isaacs R, Pruteanu-Malinici I, Siegel DL, Levine BL, June CH, Milone MC B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. , J Clin Invest , 129(6): 2019,2210-2221


Cornell RF, Ky B, Weiss BM, Dahm CN, Gupta DK, Du L, Carver JR, Cohen AD, Engelhardt BG, Garfall AL, Goodman SA, Harrell SL, Kassim AA, Jadhav T, Jagasia M, Moslehi J, O'Quinn R, Savona MR, Slosky D, Smith A, Stadtmauer EA, Vogl DT, Waxman A, Lenihan D. Prospective Study of Cardiac Evens During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. , J Clin Oncol., 37(22): 2019,1946-1955


Waxman Adam J, Clasen Suparna, Hwang Wei-Ting, Garfall Alfred, Vogl Dan T, Carver Joseph, O'Quinn Rupal, Cohen Adam D, Stadtmauer Edward A, Ky Bonnie, Weiss Brendan M Carfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis. , JAMA Oncol, 4(3): 2018,e174519


Garfall AL, Maus MV, Hwang WT, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr N D S, Bagg A, Levine BL, June CH, Stadtmauer EA Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. , The New England Journal of Medicine, 373(11): 2015,1040-7


View all publications